Recent Press Releases

Amgen Enters Into Neuroscience Collaboration With Novartis For Alzheimer's Disease And Migraine Programs

Amgen Enters Into Neuroscience Collaboration With Novartis For Alzheimer's Disease And Migraine Programs Global Co-Development and Co-Commercialization Agreement in Alzheimer's Disease With...

Ardelyx Regains NaP2b Program from Sanofi

FREMONT, Calif., Sept. 1, 2015 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced that...

Navitor Pharmaceuticals Appoints David M. Madden to Board of Directors and Michael N. Hall, PhD, to Scientific Advisory Board

Navitor Pharmaceuticals Appoints David M. Madden to Board of Directors and Michael N. Hall, PhD, to Scientific Advisory Board September 01, 2015 08:30 AM Eastern Daylight Time CAMBRIDGE, Mass.--(...

Trevena Announces Positive Results from Phase 2b Study of TRV130 in Acute Postoperative Pain

KING OF PRUSSIA, Pa.--(BUSINESS WIRE)--Trevena, Inc. (TRVN), a clinical stage pharmaceutical company focused on the discovery and development of biased ligands targeting G protein coupled receptors...

Audentes Therapeutics Acquires Cardiac Gene Therapy Company Cardiogen Sciences

Audentes Therapeutics Acquires Cardiac Gene Therapy Company Cardiogen Sciences Audentes Expands Portfolio to Include AAV Gene Therapy for Rare, Genetic Cardiac Diseases including CASQ2-CPVT, an...

GenomOncology appoints Dr. Benjamin Salisbury as Vice President, New Products and Marketing

GenomOncology appoints Dr. Benjamin Salisbury as Vice President, New Products and Marketing CLEVELAND, Sept. 1, 2015 /PRNewswire/ -- GenomOncology today announced that Benjamin Salisbury, Ph.D., has...

European Commission Grants Marketing Authorization for Kanuma™ (sebelipase alfa) for the Treatment of Patients of All Ages with Lysosomal Acid Lipase Deficiency (LAL-D)

CHESHIRE, Conn.--()--Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today that the European Commission (EC) has approved Kanuma™ (sebelipase alfa) for long-term enzyme...

European Commission Grants Marketing Authorization for Strensiq™ (asfotase alfa) for the Treatment of Patients with Pediatric-Onset Hypophosphatasia (HPP)

CHESHIRE, Conn.--()--Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) announced today that the European Commission has approved Strensiq™ (asfotase alfa) for long-term enzyme...

Valeant And AstraZeneca To Partner On Brodalumab

Valeant And AstraZeneca To Partner On Brodalumab 09/01/2015 US and EU regulatory submission planned in moderate-to-severe psoriasis in Q4 2015 LAVAL, Quebec, Sept. 1, 2015 /PRNewswire/ -- Valeant...

Intellia Therapeutics Secures $70 Million in Series B Financing

Intellia Therapeutics Secures $70 Million in Series B Financing -- Funds to Accelerate Discovery and Development of Curative Products Based on CRISPR/Cas9 Gene-Editing Technology -- -- Pipeline...

Bristol-Myers Squibb and QIMR Berghofer Medical Research Institute Announce Worldwide Collaboration to Discover Novel Immuno-Oncology Antibodies

NEW YORK & QUEENSLAND, Australia--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) and QIMR Berghofer Medical Research Institute have signed a research collaboration and license...

Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant

WOODCLIFF LAKE, N.J. and STAMFORD, Conn., Aug. 31, 2015 /PRNewswire/ -- Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., and Purdue Pharma L.P. announced today that they have...

Neurovive Pharmaceutical: NeuroVive refocuses CicloMulsion development – discontinues acute myocardial infarction indication

STOCKHOLM--Regulatory News: CicloMulsion® development to continue in acute kidney injury and increased focus on development of other drug candidates. Shareholder information meeting to be held...

FDA Grants Priority Review for Intercept's Obeticholic Acid for the Treatment of Primary Biliary Cirrhosis

NEW YORK, Aug. 31, 2015 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of...

Google's life sciences team's first major area of focus: diabetes

August 31, 2015 People living with diabetes have to keep their blood sugar levels in a normal range using a combination of diet, exercise, and medication. Yet even today, this involves a surprising...

Bristol-Myers Squibb Enters Agreement Providing Exclusive Right to Acquire Promedior, Inc. and its Novel PRM-151 in Development for Fibrotic Diseases

Bristol-Myers Squibb Company (BMY) and Promedior, Inc. announced the companies have entered into an agreement that grants Bristol-Myers Squibb an exclusive right to acquire Promedior and gain...

Bayer Expands Finerenone Clinical Development Programme with Three Phase III Studies in Patients with Chronic Heart Failure and Patients with Diabetic Kidney Disease

Decision based on data of four dose-finding studies in patients with chronic heart failure and diabetic kidney disease Berlin, August 31, 2015 – Bayer HealthCare announced today the...

Bristol-Myers Squibb Enters Agreement Providing Exclusive Right to Acquire Promedior, Inc. and its Novel PRM-151 in Development for Fibrotic Diseases

Bristol-Myers Squibb Enters Agreement Providing Exclusive Right to Acquire Promedior, Inc. and its Novel PRM-151 in Development for Fibrotic Diseases August 31, 2015 08:30 AM Eastern Daylight Time...

Celgene Completes Acquisition of Receptos, Advancing Leadership in Immune-Inflammatory Diseases

SUMMIT, N.J.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ:CELG) today announced it has closed its acquisition of Receptos, Inc. Receptos stockholders received $232.00 per share in cash, for a total...